Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PASG

Passage Bio Q1 2026 Earnings Report

Passage Bio logo
$4.10 -0.02 (-0.49%)
As of 10:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Passage Bio EPS Results

Actual EPS
-$2.36
Consensus EPS
-$2.76
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Passage Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Passage Bio Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Passage Bio's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Passage Bio's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Passage Bio Earnings Headlines

Passage Bio Amends Remix Merger, Private Financing Terms
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/passage-bio-amends-remix-merger-private-financing-terms?utm_source=marketbeat.com&utm_medium=referral
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
June 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917592-passage-bio-inc-pasg-m-and-a-call-prepared-remarks-transcript
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 5 at 1:00 AM  |  Chaikin Analytics (Ad)
PASG stock slumps 16% after-hours — what’s driving the selloff?
June 24, 2026  |  msn.comhttps://www.msn.com/en-in/money/top-stocks/pasg-stock-slumps-16-after-hours-what-s-driving-the-selloff/ar-AA26taMY
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/passage-bio-and-remix-therapeutics-announce-merger-agreement-1036273642
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3317152/0/en/passage-bio-and-remix-therapeutics-announce-merger-agreement.html
See More Passage Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email.

About Passage Bio

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases of the central nervous system. The company uses adeno-associated virus (AAV) gene therapy platforms to deliver functional genes to target cells, with the goal of addressing the underlying causes of inherited neurological disorders.

Passage Bio’s development programs have included investigational therapies for conditions such as GM1 gangliosidosis, Krabbe disease and frontotemporal dementia. Its research and development activities have been supported by collaborations with the University of Pennsylvania’s Gene Therapy Program, which has contributed expertise in vector design, manufacturing and clinical development. As with other clinical-stage biotechnology companies, its product candidates remain subject to clinical testing and regulatory review and may not receive approval.

Founded in 2018 and headquartered in Philadelphia, Passage Bio has primarily served patients and research markets through its global clinical-development and biotechnology activities rather than through commercialized products. The company became publicly traded on the Nasdaq under the symbol PASG in 2020. Its programs, partnerships and corporate strategy may evolve as clinical data and regulatory developments become available.

View Passage Bio Profile
Earnings Tools